LithiumBank Resources


Bionano Genomics Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy

Last Trade: 1.05 -0.03 -2.78

Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in... Read more

Lexaria Biosciences Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

Last Trade: 2.99 0.07 2.40

KELOWNA, BC / ACCESSWIRE / May 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces two important new patent awards. The Company has received a new granted patent in Lexaria's patent family #21: Compositions and Methods for Treating Hypertension. This is the Company's third granted US patent in this patent family. As... Read more

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Last Trade: 5.41 -0.44 -7.52

ta presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use... Read more

Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia

Last Trade: 0.18 -0.006 -3.16

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials Primary physician research found high level of interest in Tonmya as a potential new treatment option for fibromyalgia Significant dissatisfaction reported with drugs currently approved by FDA for the treatment of... Read more

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted...

Last Trade: 1.35 -0.05 -3.57

Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of drugs or other agents LOS ALTOS, Calif. / May 21, 2024 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq:... Read more

LAVA Therapeutics Provides Business Updates and Reports First Quarter 2024 Financial Results

Last Trade: 2.65 -0.05 -1.85

LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND submission Strong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands and... Read more

Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%

Last Trade: 0.81 -0.17 -17.80

NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 first quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $7,541,046 for the quarter... Read more

Regeneron Pharmaceuticals: Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England...

Last Trade: 993.95 6.68 0.68

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for... Read more

Esperion Therapeutics: Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

Last Trade: 2.41 -0.07 -2.82

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential... Read more

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as...

Last Trade: 1.79 -0.08 -4.28

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen... Read more

Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate

Last Trade: 0.15 0.0027 1.83

NORTHVALE, NJ / ACCESSWIRE / May 20, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as... Read more

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Last Trade: 3.00 0.18 6.26

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other... Read more

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

Last Trade: 0.68 -0.06 -7.98

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the renewal of its... Read more

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

Last Trade: 6.35 0.30 4.96

New production process will be developed based on Pluri’s proprietary 3D cell expansion technology Human breast milk oligosaccharides are known to shape the gut microbiota and thus provide health benefits to adults Global elderly nutrition market is valued at $25.2 billion, estimated to reach $39.7 billion in less than 10 years HAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company... Read more

Healthy Extracts Reports First Quarter 2024 Financial Results

Last Trade: 2.00 0.00 0.00

Net Revenue up 12% with Strong Subscription-Based Revenue Growth LAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / Healthy Extracts Inc. (OTCQB:HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported results for the quarter ended March 31, 2024. All... Read more

Dosing Begins in Lexaria Bioscience Comprehensive GLP-1 Animal Study

Last Trade: 2.99 0.07 2.40

Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? KELOWNA, BC / ACCESSWIRE / May 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that dosing has begun in the 12-week animal study WEIGHT-A24-1... Read more

Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

Last Trade: 0.03 -0.005 -13.51

New Initiatives Showing Encouraging Results SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023. Key financial highlights for the fourth quarter included the following: Net revenue in the fourth quarter... Read more

StageZero Life Sciences Announces Q1 2024 Financial Results and Operational Update

Last Trade: 0.04 0.00 0.00

TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients,... Read more

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Last Trade: 69.73 -1.20 -1.69

CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic... Read more

FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd

Last Trade: 0.34 -0.01 -3.00

TORONTO, ON / ACCESSWIRE / May 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), its new packaging and logo of unbuzzd™ expected to launch this summer, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to... Read more

JanOne Closes Acquisition of ALT 5 Sigma, a Leading Next Generation Blockchain Fintech

Last Trade: 3.35 0.03 0.90

LAS VEGAS, May 16, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) announced today it has closed its previously announced acquisition of blockchain financial technology provider, ALT 5 Sigma Inc., and each of its wholly-owned subsidiaries. Launched in 2018, ALT 5 is a fintech that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT 5, through... Read more

NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

Last Trade: 1.53 -0.14 -8.38

Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participants CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN)... Read more

Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA Platform

Last Trade: 0.18 -0.0043 -2.35

OTA capability enhances introduction of new assays from rapidly expanding menu ANN ARBOR, MI / ACCESSWIRE / May 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of Over-the-Air ("OTA") software and firmware update capabilities for its... Read more

Telo Genomics and Emery Pharma Announce Collaboration

Last Trade: 0.13 0.0075 6.11

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology is pleased to announce that the Company has signed a collaboration agreement with Emery Pharma ("Emery"). Emery is a full-service contract research... Read more

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

Last Trade: 1.42 0.05 3.65

LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for... Read more

PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

Last Trade: 0.02 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is fifty-one... Read more

Red Light Holland's Majority Owned AEM Farm Collaborates with Agro-Projects for Multi-Million-Dollar Mushroom Farm Expansion in Peterborough, Ontario

Last Trade: 0.04 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, is pleased to announce a... Read more

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Last Trade: 3.23 0.07 2.22

Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc.... Read more

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

Last Trade: 2.37 0.15 6.76

Expanded, experienced sales team more than doubles number of physician practices ordering CyPath® Lung test year-to-date More than 547% annualized growth rate for CyPath® Lung orders in first four months of 2024 over full-year 2023, leading to 35% increase in original 2024 forecast KOL referrals and word-of-mouth expanding adoption of CyPath® Lung outside of the beta market launch in Texas SAN ANTONIO / May... Read more

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Last Trade: 2.11 -0.04 -1.86

AUSTIN, Texas / May 15, 2024 / Business Wire / Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2024, and... Read more

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Last Trade: 0.71 -0.02 -2.51

Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024... Read more

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Last Trade: 0.83 0.0066 0.80

Revealed seven classes of promising novel drug candidates discovered using Enveric’s Psybrary™ and PsyAI™ drug discovery and artificial intelligence (AI) platforms Launched business development campaign that resulted in the execution of seven non-binding term sheets with four strategic partners that upon entering into definitive agreements and performing pursuant to the terms thereof could potentially total up to... Read more

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Last Trade: 1.68 -0.05 -2.89

First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24 Beckley Psytech’s Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b topline data expected in 2H’24 Compass Pathways’ Phase 2 study of COMP360 in PTSD patients demonstrated durable improvement in symptoms; Phase 3... Read more

Sojitz and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

Last Trade: 0.73 -0.03 -4.54

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they... Read more

Lexicon Pharmaceuticals: New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With...

Last Trade: 1.67 -0.10 -5.65

THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related events across a diverse population of patients, including patients with preserved ejection fraction (HFpEF). Researchers noted that INPEFA... Read more

Esperion Therapeutics Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

Last Trade: 2.41 -0.07 -2.82

ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. The certificate extends the term of U.S. Patent No. 7,335,799 by five years through December... Read more

Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Last Trade: 8.22 0.00 0.00

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). BIO101 (20-hydroxyecdysone) will be evaluated in obese... Read more

Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies

Last Trade: 0.90 -0.07 -7.54

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the issuance of several new patents, as well as new allowances of patent applications belonging to different Patent Families in... Read more

BetterLife Pharma Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001

Last Trade: 0.07 0.00 0.00

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral... Read more

Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules

Last Trade: 0.27 0.00 0.00

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has received a Certificate of Analysis (COA) from independent third-party laboratory testing, confirming that... Read more